期刊论文详细信息
Respiratory Research
24-h bronchodilation and inspiratory capacity improvements with glycopyrrolate/formoterol fumarate via co-suspension delivery technology in COPD
Research
Ubaldo Martin1  Shahid Siddiqui1  Colin Reisner2  Samir Arora3  James Krainson4  Faisal Fakih5  Chad Orevillo6  Luis Delacruz7  Gregory Gottschlich8  Andras Koser9  Earl St. Rose1,10  Andrea Maes1,10  Gregory Feldman1,11  Krishna Pudi1,12 
[1] AstraZeneca, Inc., Gaithersburg, MD, USA;AstraZeneca, Inc., Gaithersburg, MD, USA;Pearl Therapeutics, Inc., 280 Headquarters Plaza, East Tower, 07960, Morristown, NJ, USA;Aventiv Research, Columbus, OH, USA;Clinical Trials of Florida, Miami, FL, USA;Florida Pulmonary Research Institute, Winter Park, FL, USA;Former employee of Pearl Therapeutics, Inc., Morristown, NJ, USA;Greenville Pharmaceutical Research, Greenville, SC, USA;New Horizons Clinical Research, Cincinnati, OH, USA;Palmetto Medical Research Associates, Easley, SC, USA;Pearl Therapeutics, Inc., 280 Headquarters Plaza, East Tower, 07960, Morristown, NJ, USA;S. Carolina Pharmaceutical Research, Spartanburg, SC, USA;Upstate Pharmaceutical Research, Greenville, SC, USA;
关键词: COPD;    Muscarinic antagonists;    β-agonist;    Co-suspension delivery technology;    Metered dose inhaler;    Smoking;    Chronic bronchitis;    Emphysema;    Bronchodilator;   
DOI  :  10.1186/s12931-017-0636-4
 received in 2017-05-08, accepted in 2017-08-03,  发布年份 2017
来源: Springer
PDF
【 摘 要 】

BackgroundSymptoms of chronic obstructive pulmonary disease may vary throughout the day and it is important that therapeutic approaches provide 24-h symptom control. We report the results of two phase IIIb crossover studies, PT003011 and PT003012, investigating the 24-h lung function profile of GFF MDI (glycopyrrolate/formoterol fumarate 18/9.6 μg delivered using innovative co-suspension delivery technology) administered twice daily.MethodsPatients with moderate-to-very severe chronic obstructive pulmonary disease received 4 weeks’ treatment with each of GFF MDI, placebo MDI, and open-label tiotropium (PT003011 only). Lung function was assessed over 24 h on day 29 of each treatment period. The primary outcome was forced expiratory volume in 1 second area under the curve from 0 to 24 h (FEV1AUC0–24). Other outcomes included change from baseline in average daily rescue medication use over the treatment period. In addition, we conducted a post-hoc analysis of data pooled from both studies to further characterize the effect of GFF MDI on inspiratory capacity.ResultsGFF MDI treatment significantly increased FEV1AUC0–24 versus placebo in studies PT003011 (n = 75) and PT003012 (n = 35) on day 29 (both studies p < 0.0001), with similar improvements in FEV1AUC versus placebo for hours 0–12 and 12–24. In PT003011, improvements with GFF MDI versus tiotropium in FEV1AUC were greater during hours 12–24 compared to 0–12 h. GFF MDI treatment also resulted in a significant reduction in rescue medication use versus placebo (−0.84 [p<0.0001] and −1.11 [p=0.0054] puffs/day in PT003011 and PT003012, respectively), and versus tiotropium in PT003011 (−0.44 [p=0.017] puffs/day). A post-hoc pooled analysis showed patients treated with GFF MDI were more likely to achieve a >15% increase from baseline in inspiratory capacity than patients treated with placebo or tiotropium (72.1%, 19.0% and 47.0% of patients, respectively after the evening dose on day 29). There were no significant safety/tolerability findings.ConclusionsGFF MDI significantly improved 24-h lung function versus placebo in patients with moderate-to-very severe chronic obstructive pulmonary disease, with similar benefits in the second 12-h period compared to the first, supporting twice-daily dosing of GFF MDI.Trial registrationPearl Therapeutics, Inc.; www.clinicaltrials.gov; NCT02347072 and NCT02347085. Registered 21 January 2015.

【 授权许可】

CC BY   
© The Author(s). 2017

【 预 览 】
附件列表
Files Size Format View
RO202311104145777ZK.pdf 740KB PDF download
【 参考文献 】
  • [1]
  • [2]
  • [3]
  • [4]
  • [5]
  • [6]
  • [7]
  • [8]
  • [9]
  • [10]
  • [11]
  • [12]
  • [13]
  • [14]
  • [15]
  • [16]
  • [17]
  • [18]
  • [19]
  • [20]
  • [21]
  • [22]
  • [23]
  • [24]
  • [25]
  • [26]
  • [27]
  文献评价指标  
  下载次数:0次 浏览次数:0次